Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-6 shRNA
- Development stage
- Preclinical
- Lead developer
- Baylor College of Medicine
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
IL-6 shRNA (short hairpin RNA targeting interleukin-6) is a gene-silencing therapeutic platform designed to knock down the expression of interleukin-6 (IL-6), a key pro-inflammatory cytokine. By utilizing RNA interference (RNAi), IL-6 shRNA sequences are typically delivered via viral vectors (such as lentivirus or adeno-associated virus) or lipid nanoparticles to target cells. In oncology, IL-6 shRNA has been investigated to suppress autocrine and paracrine IL-6 signaling, which drives tumor growth, metastasis, and drug resistance in cancers like breast cancer, ovarian cancer, and osteosarcoma. Additionally, IL-6 shRNA is integrated into chimeric antigen receptor (CAR) T-cell therapies (creating ssCAR-T cells) to autonomously downregulate IL-6 expression, thereby mitigating cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) without compromising antitumor efficacy.
- Other names
- IL-6 short hairpin RNAIL6 short hairpin RNAIL 6 short hairpin RNAIL6 shRNAIL-6 shRNAIL 6 shRNAshIL-6shIL6shIL 6short hairpin RNA targeting interleukin-6
02
Targets
IL-6 (Interleukin 6)
Beyond the preview
Go deeper on IL-6 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-6 shRNA.